Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 362 participants.

Also called NCT05832931

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 362 participants (enrolled count) (from the registry)
Sponsor
Pathalys Pharma (from the registry)
Registry
  • NCT NCT05832931
  • EudraCT 2023-504338-24
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Bulgaria, Poland, Portugal, Serbia, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05832931. Randomized; triple masking; primary purpose treatment. Start 2023-04-28 (actual); primary completion 2025-07-28 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1
Acronym
PATH-1
Condition
Secondary Hyperparathyroidism
Condition
End-stage Kidney Disease (ESKD)
Intervention (Drug)
PLS240
Intervention (Drug)
Placebo
Intervention (Drug)
Open-Label Extension PLS240
Lead sponsor
Pathalys Pharma (class: industry)
Collaborator
Launch Therapeutics (class: not stated)

Record details

Record id
cardio:ct-nct05832931
Content hash
f935ceb30144b1358e28d9c98cd0b6ead2faf7f44d1bf215447acd6bfdd5e9a8